India's Aurobindo Pharma rises after facility clears US drug regulator's probe - TradingView
Yesterday • Google News
Aurobindo Pharma Limited (AUROPHARMA)
NSEINR 1174.150.89%
Price Chart
Key Statistics
Market Cap
INR 675.94B
P/E Ratio
19.45
Revenue (TTM)
INR 309.22B
Volume
377.21K
52W High
INR 1592.00
52W Low
INR 995.30
Dividend Yield
0.00%
Beta
0.66
Technicals
50-Day MA
1143.13
200-Day MA
1316.559
52 Week High
1592
52 Week Low
995.3
About AUROPHARMA
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto R.
Employees
26015
Headquarters
Hyderabad, India
CEO
Mr. Kambam Nithyananda Reddy
Latest News
Environment, Social and Governance (ESG) Risk Ratings
Total ESG Risk Score
38.43
Percentile: 81.1
Environmental Risk Score
3.81
Percentile: 2
Social Risk Score
21.42
Percentile: 2
Governance Risk Score
16.2
Percentile: 2
Controversy Level
ESG data provided by Sustainalytics, Inc.
AUROPHARMA
Category Average
3Significant Controversy Level
NoneSevere
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg